Clinical Trial for MASH

A Clinical Study of Efinopegdutide in People with Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH). Researchers want to learn if a study medicine called efinopegdutide can treat MASH. The goals of this study are to learn:

• If efinopegdutide can lower the amount of fat, inflammation, and scarring (fibrosis) in the liver

• About the safety of efinopegdutide and how well people tolerate it

Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis
 
Eligibility Requirements:

Inclusion Criteria

• 18 to 80 years of age

• Has compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH)

• Has either type 2 diabetes that is controlled by diet or medication, or does not have type 2 diabetes

Exclusion Criteria

• Has history of a liver disease other than MASH, for example, Hepatitis B or C, drug-induced liver disease, or autoimmune liver disease

• Has history of type 1 diabetes

• Major illnesses like recent (within 6 months of study entry) episodes of heart problems, such as congestive heart failure, unstable angina, heart attack, stroke, or mini-stroke

All study participants will receive the assigned study treatment, study-related medical exams, and study-related laboratory tests at no cost. Further details about study support can be discussed with the study team.